We are international

Prognostic criteria are used to classify patients by the type of disease and stage of disease. Prognostic criteria provide ways to semgent the patient population. This segmentation allows scientists to analyze clinical trial results and other treatment experience data to provide more information to physicians and their patients making decisions on appropriate treatment.

Development Of An International Prognostic Index For Classification And Monitoring MM: Dr. Phillip Greipp

Dr. Greipp presented the recommendations f for a new International Prognostic Index from the International Myeloma Working Group. The effort was sponsored by the IMF and its objective is to develop a simple, universally accepted staging system to replace the now decades-old Durie-Salmon system.

The system uses only two measures: beta 2 microglobulin (β2m) and serum albumin.

The Major Prognostic Valye Of Cytogenetics In Multiple Myeloma: Dr. Guido Tricot

Dr. Tricot presented an analysis of prognostic factors for the patients who participated in Little Rock's Total Therapy I (TT-I) program. A univariate analysis (which looks at whether a factor in and of itself is predictive) of Overall Survival (OS) and Event Free Survival (EFS) showed six factors with strong relationships (see below)

A multivariate analysis (which brings factors in one at a time based on how much predictive value they add showed that cytogenetics (see Hypo, CA 13, MM-MDS below) were the most relevant facors, followed by four common blood values (see below) and then age.

Dr. Tricot presented results showing that the presence of zero to three of the risk factors identified can separate patients into four groups with distinctly different survival curves.

The Importance Of Imaging In Myeloma Staging, Prognostic Classification And Monitoring:  Dr. Brian Durie

Dr. Durie discussed the role of imaging, particularly focusing on PET and MRI scans in myeloma.

Role Of Free Light Chain Monitoring In Disease Diagnosis And Monitoring: Dr. A. Bradwell

Dr. Bradwell presented an overview of a new assay that measures free light chains in the blood and the potential advantages over present tests that use 24 hour urine collections.

The assay is especially useful for non-secretory patients for whom traditional urine and serum IEP cannot detect disease activity.

Investigation Of Residual Disease By Quantitative PCR In Multiple Myleoma:  Dr. Paolo Corradini

Dr. Corradini discussed use of PCR to monitor minimal residual disease in patients who have undergone allogeneic transplantation..

Immunophenotypic Investigation Of Minimal Residual Disease In Multiple Myeloma

Dr. San Miguel discussed the role of immunophenotyping in following patients with Minimal Resifual Disease( MRD)

Quantitation Of Post Transplant Tumor Load In The Bone Marrow By PCR With Alele-Specific Oligonucleotide Primers Is A Prognostic Parameter In MM:  Dr. M. Bakkus

Dr. Bakkus discussed the prognostic value of tumor cell counts in post-transplant patients developed using PCR in predicting survival.

The panel (below) fielded questions at the end of the session.

Please note that the Unknown Patient is a patient, not a doctor and not a scientist. This summary represents a layman's view of what was said at the conference and should form a basis for raising awareness of issues that could be discussed with a qualified professional. In no way should anything contained in this report be taken as medical advice or form the basis for action without first consulting a qualified medical professional who is familiar with your specific medical situation.